Repros Therapeutics (RPRX) says the FDA has provided guidance for a Phase 2 study of its low...

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

Repros Therapeutics (RPRX) says the FDA has provided guidance for a Phase 2 study of its low dose oral Proellex for the treatment of endometriosis. The drug developer plans to submit the revised protocol as soon as practicable. Once received, the FDA has agreed to review the design within 30 days, for which, if accepted, would enable RPRXto commence Phase 2 trials in as early as Q4.